Securities code: Nanjing Hicin Pharmaceutical Co.Ltd(300584) securities abbreviation: Nanjing Hicin Pharmaceutical Co.Ltd(300584) Announcement No.: 2022028 Nanjing Hicin Pharmaceutical Co.Ltd(300584)
Announcement on the implementation of equity distribution in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Nanjing Hicin Pharmaceutical Co.Ltd(300584) (hereinafter referred to as “the company” or “the company”) the 2021 profit distribution plan has been deliberated and approved by the 2021 annual general meeting of shareholders held on May 16, 2022, and the announcement of the resolution of the general meeting of shareholders has been disclosed on the gem information disclosure website designated by the CSRC on the same day. The distribution of rights and interests is hereby announced as follows:
1、 Profit distribution plan approved by the general meeting of shareholders
1. The company held the 2021 annual general meeting of shareholders on May 16, 2022 and approved the plan for profit distribution in 2021. The profit distribution plan for 2021 is to distribute cash dividends of RMB 2.5 (tax included) for every 10 shares to all shareholders based on the 120000000 shares of the company’s share capital on December 31, 2021, with a total of RMB 30000000 (tax included), In this year, it is proposed not to convert the accumulation fund into share capital or give bonus shares. The remaining undistributed profits will be accumulated to the next year to support the operation and development of the company. If the total share capital of the company changes due to the conversion of convertible bonds into shares, share repurchase, equity incentive exercise, refinancing and listing of new shares before the implementation of the distribution plan, the distribution proportion will be adjusted accordingly according to the principle that the total distribution amount remains unchanged.
2. The total share capital of the company has not changed from the disclosure of the distribution plan to the implementation period.
3. The distribution plan implemented by the company this time is consistent with the distribution plan deliberated and approved by the company’s 2021 annual general meeting of shareholders.
4. The implementation of the distribution plan of the company is less than two months from the deliberation and approval of the general meeting of shareholders. 2、 Equity distribution scheme
The company’s equity distribution plan for 2021 is: Based on the company’s existing share capital of 120000000 shares, Distribute cash dividends of RMB 2.5 per 10 shares to all shareholders (tax included; after tax deduction, QFII, rqfii and individuals holding pre IPO restricted shares and securities investment funds will pay 2.25 yuan for every 10 shares; the individual dividend tax on post IPO restricted shares, equity incentive restricted shares and unlimited tradable shares will be levied at a differentiated tax rate, and the company will not withhold individual income tax temporarily. When individuals transfer shares, the tax payable will be calculated according to their holding period [note] ； The red profit tax involved in securities investment funds holding post IPO restricted shares, equity incentive restricted shares and unlimited tradable shares will be levied at 10% on the fund units held by Hong Kong investors and at a differentiated tax rate on the fund units held by mainland investors). In this year, no provident fund will be used to increase share capital and no bonus shares will be given.
[Note: according to the principle of first in, first out, the holding period is calculated by taking the investor’s securities account as the unit. If the holding period is less than 1 month (including 1 month), the supplementary tax is 0.5 yuan for every 10 shares; if the holding period is more than 1 month to 1 year (including 1 year), the supplementary tax is 0.25 yuan for every 10 shares; if the holding period is more than 1 year, the supplementary tax is not required.]
3、 Equity registration date and ex dividend date
1. The registration date of equity distribution is May 24, 2022;
2. Ex right and ex interest date: May 25, 2022.
4、 Equity distribution object
The objects of this distribution are: all shareholders of the company registered with China Securities Depository and Clearing Co., Ltd. Shenzhen Branch (hereinafter referred to as “CSDCC Shenzhen Branch”) after the closing of Shenzhen Stock Exchange on the afternoon of May 24, 2022.
5、 Equity distribution method
1. The cash dividends entrusted by the company to CSDCC Shenzhen Branch will be directly transferred to its capital account through the shareholder custody securities company (or other custody institution) on May 25, 2022.
2. The cash dividends of the following A-share shareholders shall be distributed by the company itself:
Serial number shareholder account number shareholder name
1 02 300 Cao Yuping
2 01 551 Jiang Xiaoqun
3 02 905 Liu Xiaoquan
4 02 252 Yao Xiaomin
During the application period of equity distribution business (application date: May 17, 2022 to registration date: May 24, 2022), if the cash dividend entrusted to China Clearing Shenzhen Branch is insufficient due to the reduction of shares in the securities account of the shareholders, all legal liabilities and consequences shall be borne by our company.
6、 Advisory body
Consulting organization: Securities Department of the company consulting address: No. 1, HENGFA Road, Nanjing Economic and Technological Development Zone, Jiangsu Province (post code: 210046) consulting Tel.: 02583241873 consulting Fax: 02585514865 consulting email: [email protected]. 7、 Documents for future reference 1. Resolutions of the 2021 annual general meeting of shareholders; 2. Resolutions of the 19th meeting of the third board of directors; 3. Documents confirming the specific time arrangement of dividend distribution by CSDCC Shenzhen Branch; 4. Other documents required by Shenzhen Stock Exchange. It is hereby announced.
Nanjing Hicin Pharmaceutical Co.Ltd(300584) board of directors may 18, 2022
